Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $185 to $205.Copyright © Benzinga. All rights reserved. Write to [email protected] with any questions about this content. Benzinga does not provide investment advice.© 2024 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved.
Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.43 |
Change
-0.350(1.07%) |
Mkt cap ! $20.69B | |||
| Open | High | Low | Value | Volume |
| $32.61 | $32.65 | $32.39 | $32.20M | 991.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6572 | $32.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.45 | 150 | 1 |
View Market Depth
| Last trade - 16.10pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.41 |
Change
-0.350 ( 1.30 %) |
||||
| Open | High | Low | Volume | ||
| $32.63 | $32.64 | $32.39 | 114517 | ||
| Last updated 15.59pm 20/05/2024 ? | |||||
| RMD (ASX) Chart |